[1]叶大铸,马寄晓.奥曲肽及其类似物用于肿瘤诊断的进展[J].国际放射医学核医学杂志,2003,27(3):97-100.
　YE Da-zhu,MA Ji-xiao.Advances in tumor diagnosis with labeled somatostatin analogues[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(3):97-100.
点击复制

奥曲肽及其类似物用于肿瘤诊断的进展(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
27
期数:
2003年第3期
页码:
97-100
栏目:
专家论坛
出版日期:
1900-01-01

文章信息/Info

Title:
Advances in tumor diagnosis with labeled somatostatin analogues
作者:
叶大铸1;  马寄晓2
1. Memorial Sloan-Zettering Cancer Center USA, NewYork, 10021;
2. 200233 上海, 上海交通大学第六人民医院核医学科
Author(s):
YE Da-zhu1;  MA Ji-xiao2
1. Memorial Sloan-Kettering Cancer Center, New York, 10021, USA;
2. Shanghai Jiaotong University Sixth People’s Hospital, Shanghai 200233, China
关键词:
奥曲肽; 生长抑素; 嗜铬细胞瘤; 副神经节瘤; 神经母细胞瘤; 甲状腺髓样癌
Keywords:
octreotide; somatostatin; pheochromocytoma; paraganglioma; neuroblastoma; medullary thyroid cancer
分类号:
R817.4
摘要:
简要综述111In-奥曲肽和99Tcm-NeoTec在肿瘤诊断中的应用,其对类癌、甲状腺髓样癌、来自胰腺或上消化道的神经内分泌肿瘤的诊断和随访有重要价值,对失去摄碘功能的分化型甲状腺癌、甲亢性突眼、肉样瘤病的肉芽肿过程也可得到阳性结果。应用放射性核素标记的生长抑素类似物使肿瘤成功的显像,可发展并应用标记的类似物来治疗这些肿瘤。生长抑素类似物的标记技术扩展了应用其他肽类进行分子显像的研究兴趣。
Abstract:
Values of 111In-octreotide and 99Tcm-NeoTec in tumor diagnosis are briefly reviewed. There are great values in diagnosis and follow up for patients with carcinoid tumor, medullary cancer of thyroid, and neuroendocrine tumors from pancreas or upper respiratory tract.Somatostatin receptors are also distributed in organs outside the classical neuroendocrine tissues. Positive studies are also found in patients with differentiated cancer of thyroid whose tuor have lost iodide concentrating ability, exophthalmos in Graves’ disease or granulomatous process in sarcoidosis. The successes of tumor imaging with labeled somatostatin analogues have led to the development of radionuclide therapy for these tumors with the labeled analogues.The technics in labeling of somatostatin analogues have also led the expanded interests and studies of other peptides in molecular imaging.

参考文献/References:

[1] Boerman OC, Oyen WJG, Corstens FHM. Radio-labeled receptor binding peptides:a new class of radiopharmaceu-tical[J]. Semin Nucl Med, 2000, 30:195-208.
[2] Meko JB, Doherty GM, Siegel BA, et al. Evaluation of somatostatin receptor scintigraphy for detecting neuroendocrine tumors[J]. Surgery, 1996, 120:975-984.
[3] Slooter GD, Mearadji A, Breeman WAP, et al. Somatostatin receptor imaging,therapy and new strategies in patients with neuroendocrine tumors[J].Brit J Surg,2001,88:31-40.
[4] Warner RRP, O’Dorisio TM. Radiolabeled peptides in diagnosis and tumor imaging:clinical overview[J]. Semin Nucl Med, 2002, 32:79-93.
[5] Merrell RC. Octreotide scintigrapy[J]. Ann Surg, 1996, 264:117-118.
[6] Papotti M, Kumar U, Volante M, et al. Immunohisto-chemical detection of somatostatin types 1-5 in medullary carcinoma of the thyroid[J]. Clin Endocrinol, 2001, 54:641-649.
[7] Menda Y, Kahn D. Somatostatin receptor imaging of nonsmall cell lung cancer with 99m Tc depreotide[J]. Semin Nucl Med, 2002, 32:92-96.
[8] van de Wiele C, van Belle S, Sieghers G, et al. Receptor imaging in breast carcinoma:future prospects[J]. Eur J Nucl Med, 2001, 28:675-679
[9] Virgolini I, Traub T, Leimer M, et al. New radiopharma-ceuticals for receptor scintigraphy and radionuclide thera-py[J]. Quart J Nucl Med, 2000, 14:50-58.
[10] La mbe rts SWJ, de Herder WW, Hofland LJ. Somato-statin analogs in the diagnosis and treatment of cancer[J]. Trends Endocrinol Metab, 2002, 13:451-457.
[11] McCarthy KE, Woltering EA, Epennan GD,et al. In situ radiothetapy with 111 In pentetreotide:initial observations and future directions[J]. Cancer J, 1998, 494-502.
[12] Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging[J]. Semin Nucl Med, 2002, 32:84-91.
[13] Buetow PC, Miller DL, Parrino TV, et al. Islet cell tumors of the pancreas:Clinical, radiologic, and pathologic correlation in the diagnosis and localization[J]. Radiographic, 1997, 17:1010.
[14] Marcos HB, Libutti SK, Alexander HR, et al. Neuroendocrine tumors of the pancreas in von Hippel-Lindau disease; Spectrum of appearance at CT and MR imaging of with histopathologic comparison[J]. Radiology, 2002, 203:751-758.
[15] Valle N, Catargi B, Ronei N, et al. Evaluation of Indium 111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy[J]. Thyroid, 1999, 9:583-589.
[16] Krassas GE, Dumas A, Kaltsas T, et al. Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease[J]. Thyroid, 1999, 9:47-52.
[17] Weiner RE, Thakur ML. Radilabeled peptides in the diagnosis and therapy of oncological diseases[J]. Appl Radiat Isot, 2002, 57:749-763.
[18] Oberg K. Established clinical use of octreotide and lan-reotide in oncology[J]. Chemotherapy, 2001,47:s 40-s 63.
[19] Signore A, Annovazzi A, Chianelli M, et al. Peptide radiopharmaceuticals for diagnosis and therapy[J]. Eur J Nucl Med, 2001, 28:1555-1556.

相似文献/References:

[1]夏伟,吕中伟,王国玉,等.99Tcm标记depreotide及与肺腺癌A549细胞亲和性研究[J].国际放射医学核医学杂志,2010,34(4):193.[doi:10.3760/cma.j.issn.1673-4114.2010.04.001]
　XIA Wei,LÜ,Zhong-wei,et al.Experimental studies of depreotide labeled with 99Tcm and the affinity with human lung adenocarcinoma cell line A549[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):193.[doi:10.3760/cma.j.issn.1673-4114.2010.04.001]
[2]高玉婷,王自正.生长抑素类似物介导靶向显像及治疗的研究现状和进展[J].国际放射医学核医学杂志,2009,33(6):330.[doi:10.3760/cma.j.issn.1673-4114.2009.06.003]
　GAO Yu-ting,WANG Zi-zheng.The development of somatostatin analogues mediated tumor targeting and therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(3):330.[doi:10.3760/cma.j.issn.1673-4114.2009.06.003]
[3]侯仁花,吕中伟.生长抑素受体显像剂99mTc-depreotide的研究进展[J].国际放射医学核医学杂志,2008,32(1):15.
　HOU Ren-hua,LÜ,Zhong-wei.The progress of a new somatostatin receptor agent 99mTc-depreotide[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(3):15.
[4]苏燕,王峰,王自正,等.131Ⅰ-Tyr-octreotide的标记方法学及其生物学分布的研究[J].国际放射医学核医学杂志,2007,31(5):257.
　SU Yan,WANG Feng,WANG Zi-zheng,et al.abeling mothod and biodistribution of 131Ⅰ-Tyr-octreotide[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(3):257.
[5]王秀娟,李险峰.生长抑素受体肿瘤显像的临床应用及研究进展[J].国际放射医学核医学杂志,2006,30(4):217.
　WANG Xiu-juan,LI Xian-feng.Clinical application and progress of somatostatin receptor imaging in diagnosis of cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(3):217.
[6]郭睿,晋建华.99mTc-depreotide生长抑素受体显像的临床应用研究[J].国际放射医学核医学杂志,2007,31(3):154.
　GUO Rui,JIN Jian-hua.The clinical application and study of 99mTc-depreotide somatostatin receptor imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(3):154.
[7]宋进华,王自正,周云,等.188Re-奥曲肽在荷瘤裸鼠体内分布的实验研究[J].国际放射医学核医学杂志,2006,30(1):14.
　SONG Jin-hua,WANG Zi-zheng,ZHOU Yun,et al.Experimental study on biodistribution of 188Re-octreotide in nude mice[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(3):14.
[8]罗全勇.多肽受体靶向放射治疗:现状与进展[J].国际放射医学核医学杂志,2005,29(2):74.
　LUO Quan-yong.Peptide receptor radionuclide therapy: current status and future directions[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(3):74.
[9]周玉凤.放射性核素标记小分子多肽治疗肿瘤的研究进展[J].国际放射医学核医学杂志,2005,29(3):105.
　ZHOU Yu-feng.The recent development of receptor targeting therapy for tumors with radiopeptides[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(3):105.
[10]段炼,李险峰.甲状腺相关眼病与生长抑素受体显像[J].国际放射医学核医学杂志,2005,29(3):108.
　DUAN Lian,LI Xian-feng.Thyroid associated ophthalmopathy and somatostatin receptor scintigraphy[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(3):108.
[11]刘淼,刘兴党.生长抑素受体显像剂99Tcm-奥曲肽的SPECT研究[J].国际放射医学核医学杂志,2012,36(3):138.[doi:10.3760/cma.j.issn.1673-4114.2012.03.003]
　LIU Miao,LIU Xing-dang.Development of study on SPECT imaging with radioisotope 99Tcm-octreotide[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):138.[doi:10.3760/cma.j.issn.1673-4114.2012.03.003]
[12]王佳琼,王自正,姚薇萱,等.乳腺肿瘤生长抑素受体表达与生长抑素受体显像[J].国际放射医学核医学杂志,2006,30(1):17.
　WANG Jia-qiong,WANG Zi-zheng,YAO Wei-xuan,et al.Somatostatin receptor scintigraphy and somatostatin receptors expression in breast neoplasm[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(3):17.
[13]马寄晓,叶大铸.奥曲肽及其类似物用于肿瘤治疗的进展[J].国际放射医学核医学杂志,2005,29(2):79.
　MA Ji-xiao,YE Da-zhu.Advances in tumor treatment with labeled somatostatin analogues[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(3):79.
[14]章斌.188Re直接标记octreotide的方法学[J].国际放射医学核医学杂志,2002,26(5):220.
　ZHANG Bin.Investigations of directly labelling octreotide with 188Re[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(3):220.

备注/Memo

备注/Memo:
收稿日期:2002-12-02。
作者简介:叶大铸(1926-),男,教授,主要从事核医学研究。;马寄晓(1926-),男,教授,主要从事临床核医学研究。
更新日期/Last Update: 1900-01-01